Many drug candidates fail in the later stages of development due to unacceptable toxicity. These clinical trial setbacks often stem from the limited predictive power of early-stage screening models. Three-dimensional (3D) organoids offer a promising alternative, as they have the potential to improve the accuracy of in vitro assays, highlighting their value in pre-clinical testing.
Image Credit: Melnikov Dmitriy/Shutterstock.com
The most prevalent side effects of anti-cancer drugs are their toxicity to the intestine, which often restricts the dosage that can be administered to patients. In vitro assays utilizing 3D organoids can effectively assess the toxic effects of anti-cancer compounds, providing critical information throughout the drug development process.
The application of automated high-content imaging increases throughput and broadens the scope of information regarding toxicity effects, particularly in relation to complex 3D biological models.
This study demonstrates how toxic effects in intestinal organoids can be evaluated and quantified using high-content imaging.
The article presents a method developed to assess toxicity in 3D mouse intestinal organoids cultured in Matrigel domes, where the concentration-dependent phenotypic effects of 10 compounds were tested.
Download the full app note
Acknowledgments
Produced from material originally authored by Oksana Sirenko and Krishna Macha from Molecular Devices.
About Molecular Devices UK Ltd
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California, with offices around the globe. For more information, please visit www.moleculardevices.com.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.